Adicet Bio (ACET) Investor presentation summary

Pipeline and clinical programs

• Advancing allogeneic γδ1 CAR-T cell therapies for autoimmune diseases and cancer, with prula-cel targeting CD20 in multiple autoimmune indications and ADI-212 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC).

• Prula-cel is enrolling multiple cohorts in lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and rheumatoid arthritis (RA), with clinical updates and pivotal study initiation planned through 2026.

• ADI-212, a gene-edited and armored CAR-T, is in preclinical development for mCRPC, with regulatory filing and trial initiation expected in late 2026.

Prula-cel clinical data and impact

• Single-dose prula-cel showed rapid, sustained reductions in disease activity (SLEDAI-2K, PGA) and improved kidney function in all LN patients, with three complete and two partial renal responses.

• All patients discontinued immunosuppressants and tapered corticosteroids to zero or physiological levels.

• Well-tolerated safety profile: no ≥Grade 2 cytokine release syndrome (CRS), no ICANS, and only low-grade infections, supporting outpatient administration.

• Evidence of immune reset with emergence of naïve B cell repertoire and depletion of dominant, potentially pathogenic B cell clones.

• Off-the-shelf availability eliminates need for leukapheresis and manufacturing delays.

Unmet needs and market opportunity

• Current therapies for LN/SLE offer limited disease control, frequent flares, and significant side effects, highlighting the need for one-time therapies with favorable safety profiles.

• Prula-cel is being developed across seven autoimmune indications, with potential to change clinical practice for diseases affecting hundreds of thousands in the US.

• ADI-212 targets a significant market in mCRPC, where current treatments have poor outcomes and high unmet need; PSMA-targeted therapies like Pluvicto have shown benefit but leave room for improved safety and efficacy.